期刊
PHARMACOGENOMICS JOURNAL
卷 10, 期 4, 页码 247-257出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2010.34
关键词
microarray; cross-platform; gene signature; classifier; MAQC; hepatotoxicity
资金
- Chinese Key Technologies RD Program [2005CB23402]
- National Science Foundation of China [30801556]
- Research Fund for the Doctoral Program of Higher Education of China [20090101110126]
Microarray-based classifiers and associated signature genes generated from various platforms are abundantly reported in the literature; however, the utility of the classifiers and signature genes in cross-platform prediction applications remains largely uncertain. As part of the MicroArray Quality Control Phase II (MAQC-II) project, we show in this study 80-90% cross-platform prediction consistency using a large toxicogenomics data set by illustrating that: (1) the signature genes of a classifier generated from one platform can be directly applied to another platform to develop a predictive classifier; (2) a classifier developed using data generated from one platform can accurately predict samples that were profiled using a different platform. The results suggest the potential utility of using published signature genes in cross-platform applications and the possible adoption of the published classifiers for a variety of applications. The study reveals an opportunity for possible translation of biomarkers identified using microarrays to clinically validated non-array gene expression assays. The Pharmacogenomics Journal (2010) 10, 247-257; doi: 10.1038/tpj.2010.34
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据